Dr. Andrew L. Salzman

• 
  www.inotekcorp.com/print.asp?Print=board_of_directors&N - [Cached Version]
  Published on: 3/15/2007    Last Visited: 3/15/2007  

  Andrew Salzman, MD
  
  President & CEO, Inotek Pharmaceuticals

• 
  www.inotekcorp.com/print.asp?Print=board_of_directors&N - [Cached Version]
  Published on: 1/6/2008    Last Visited: 1/6/2008  

  Andrew Salzman, MD
  
  Past President & CEO, Inotek Pharmaceuticals

• 
  www.inotekcorp.com/content/management_team.asp - [Cached Version]
  Published on: 3/15/2007    Last Visited: 3/15/2007  

  Andrew L. Salzman, MDPresident & Chief Executive Officer

• 
  www.coloherp.org/cb-news/Vol-31/cbn-0401/Komodo.php - [Cached Version]
  Published on: 1/1/2004    Last Visited: 3/24/2007  

  "We're still working on defining what molecule is in Komodo dragon blood that appears to be antibacterial," says Andy Salzman of Inotek Pharmaceuticals in Beverly, Massachusetts, who is now trying to identify the substance for Fredeking.

• 
  www.venturenortheast.com/topstories-view.php?id=3350 - [Cached Version]
  Published on: 8/24/2007    Last Visited: 11/24/2007  

  It will also fund the expansion of our development team to support our long-term growth," said Andrew Salzman, M.D., Inotek's President & CEO.

• 
  www.inotekcorp.com/print.asp?Print=management_team&News - [Cached Version]
  Published on: 3/15/2007    Last Visited: 3/15/2007  

  Andrew L. Salzman, MDPresident & Chief Executive Officer

• 
  www.baseballist.com/v-cgi/feeds.cgi?feedid=52&story_id= - [Cached Version]
  Published on: 3/9/2001    Last Visited: 3/9/2006  

  "I am excited that Emma has decided to join Inotek," commented Dr. Andrew Salzman, Inotek's President and CEO.

• 
  www.pitango.com/news_item.asp?ID=870 - [Cached Version]
  Published on: 8/23/2007    Last Visited: 2/22/2008  

  It will also fund the expansion of our development team to support our long-term growth," said Andrew Salzman, M.D., Inotek's President & CEO.

• 
  www.hbshealth.org/events/event.cfm?CFID=457460&CFTOKEN= - [Cached Version]
  Published on: 5/12/2004    Last Visited: 2/25/2008  

  Andrew L. Salzman, MD - President and Chief Executive Officer, Inotek Pharmaceuticals Corporation Prior to founding Inotek, he established and was head of the Division of Critical Care Medicine at Children's Hospital Medical Center (Cincinnati) and Associate Professor of Pediatrics and Molecular Physiology at the University of Cincinnati College of Medicine.Dr. Salzman received a B.A. from Yale University, an M.D. from the Harvard Medical School, pediatric residency training at Columbia University, pediatric infectious disease fellowship training at at Children's Hospital (Boston), and pediatric critical care training at Massachusetts General Hospital.Dr. Salzman conducted post-doctoral studies at Children's Hospital Medical Center (Boston), Massachusetts General Hospital, Beth Israel Hospital (Boston), and the Weizmann Institute of Science (Rehovot, Israel).

• 
  www.inotekcorp.com/print.asp?Print=&News=23 - [Cached Version]
  Published on: 4/10/2007    Last Visited: 12/11/2008  

  "We now have support for PARP inhibition as a potential method of suppressing brain inflammation and preventing injury following ischemia-reperfusion," said Andrew Salzman, M.D., President and Chief Executive Officer of Inotek.

Page:  1 2 3 4 5